1. Short title This Act may be cited as the Improving Medicare Beneficiary Access to Innovative Diabetes Technologies Act of 2019 . 2. Establishment of HHS Task Force on coverage and payment for innovative diabetes technologies and services (a) Definitions In this section: (1) CMS The term CMS means the Centers for Medicare & Medicaid Services. (2) FDA The term FDA means the Food and Drug Administration. (3) Innovative diabetes technologies and services The term innovative diabetes technologies and services means medical technologies and services for the treatment and management of diabetes for which coverage is not available under the Medicare fee-for-service program. (4) Medicare The term Medicare means the program of health insurance for the aged and disabled established under title XVIII of the Social Security Act. (5) Medicare beneficiary The term Medicare beneficiary means an individual who is entitled to benefits under part A of title XVIII of the Social Security Act, or enrolled under part B of such title, or both. (6) Secretary The term Secretary means the Secretary of Health and Human Services. (b) Establishment; mission (1) Establishment There is established within the Office of the Secretary the Task Force on Innovative Diabetes Technologies and Services (in this section referred to as the Task Force ). (2) Mission The mission of the Task Force is to— (A) advise the Secretary with respect to accessibility to innovative diabetes technologies and services under Medicare; (B) make recommendations to support current and future access to innovative diabetes technologies and services under Medicare